Business Standard

Biocon IPO after integration of Viatris market: MD & CEO Shreehas Tambe

'From our perspective, we have operated with a high band and a lower band model'

Shreehas Tambe, managing director and chief executive officer of Biocon Biologics
Premium

Shreehas Tambe, managing director and chief executive officer of Biocon Biologics

Shine Jacob

Listen to This Article

After the acquisition of Viatris’ global biosimilars business last year and Serum Institute Life Sciences doubling its investments to $300 million, Biocon Biologics (BBL), a subsidiary of Biocon, is gearing up for an initial public offering (IPO) now. Shreehas Tambe, managing director (MD) and chief executive officer (CEO) of Biocon Biologics talks about the company’s IPO roadmap, investment plans and Viatris integration, in a Zoom interview with Shine Jacob. Edited excerpts:

Serum Institute of India doubled its investment to $300 million in BBL, which is also backed by private equity (PE) investors. What is the plan ahead? How are PEs looking

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: May 24 2023 | 9:48 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com